CN108822070A - 一种用于检测同型半胱氨酸结构荧光探针对位化合物及其应用 - Google Patents
一种用于检测同型半胱氨酸结构荧光探针对位化合物及其应用 Download PDFInfo
- Publication number
- CN108822070A CN108822070A CN201810606849.1A CN201810606849A CN108822070A CN 108822070 A CN108822070 A CN 108822070A CN 201810606849 A CN201810606849 A CN 201810606849A CN 108822070 A CN108822070 A CN 108822070A
- Authority
- CN
- China
- Prior art keywords
- homocysteine
- compound
- fluorescence intensity
- application
- fluorescence probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical group OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 title claims abstract description 37
- 239000000523 sample Substances 0.000 title claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims description 16
- 239000012895 dilution Substances 0.000 claims description 6
- 238000010790 dilution Methods 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 abstract description 5
- 150000001413 amino acids Chemical class 0.000 abstract description 5
- 238000001514 detection method Methods 0.000 abstract description 4
- 235000018417 cysteine Nutrition 0.000 abstract description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract description 3
- 238000005259 measurement Methods 0.000 abstract description 3
- 238000005935 nucleophilic addition reaction Methods 0.000 abstract description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
- C07D311/82—Xanthenes
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1007—Non-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1088—Heterocyclic compounds characterised by ligands containing oxygen as the only heteroatom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
本发明涉及临床医疗领域,尤其涉及一种用于检测同型半胱氨酸结构荧光探针对位化合物及其应用,具有如下的结构:通过对荧光强度的测定可有效看出本探针可以和同型半胱氨酸结构中的氨基和琉基基团特异性的发生亲核加成反应,共辄体的空间结构发生变化,引起体系中荧光强度增强,可选择性检测同型半胱氨酸,与半胱氨酸和其它氨基酸不响应。
Description
技术领域
本发明涉及临床医疗领域,尤其涉及一种用于检测同型半胱氨酸结构荧光探针对位化合物及其应用。
背景技术
同型半胱氨酸(Homocysteine,HCY)又称高半胱氨酸,是一种含硫氨基酸且不属于组成蛋白质的20种氨基酸,体内不能合成,只能来源于蛋氨酸(甲硫氨酸)的分解代谢。正常情况下,血HCY含量甚微,一般空腹总HCY水平为5umol/L-15umol/L;轻度、中度、重度高HCY血症患者浓度分别为16umol/L-30umol/L、31umol/L-100umol/L、大于100umol/L。研究证实:高浓度的HCY是冠状动脉疾病、脑血管疾病、外周血管疾病独立的危险因子,危险度随着浓度的升高而增加。因此监测和降低同型半胱氨酸的浓度,具有十分重要的临床意义。
发明内容
本发明所要解决的技术问题是,克服现有技术中存在的不足,提供一种检测同型半胱氨酸结构荧光探针对位化合物及其应用。
一种用于检测同型半胱氨酸结构荧光探针对位化合物,具有如下的结构:
一种用于检测同型半胱氨酸结构荧光探针对位化合物应用,
a.化合物的稀释
称取上述化合物0.1g于1.5mlEP管中,加入1ml蒸馏水,溶解,混匀,梯度稀释至300倍;
b.化合物的荧光测定
取96孔黑色微孔板,加入上述化合物各100μl,激发光280nm,发射光590nm,测定其荧光强度;
c.同型半胱氨酸的荧光测定
取96孔黑色微孔板,加入同型半胱氨酸0μmol、1μmol、2μmol、5μmol、10μmol、20μmol、50μmol、和100μmol的同型半胱氨酸各100μl加入上述化合物各100μl,37度孵育10min,激发光280nm,发射光590nm,测定其荧光强度。
本发明的有益效果是:
通过对荧光强度的测定可有效看出本探针可以和同型半胱氨酸结构中的氨基和琉基基团特异性的发生亲核加成反应,共辄体的空间结构发生变化,引起体系中荧光强度增强,可选择性检测同型半胱氨酸,与半胱氨酸和其它氨基酸不响应。
附图说明
图1是探针与同型半胱氨酸反应的线性图。
具体实施方式
为了使本技术领域的技术人员更好地理解本发明的技术方案,下面结合附图和最佳实施例对本发明作进一步的详细说明。
本发明一种用于检测同型半胱氨酸结构荧光探针对位化合物,具有如下的结构:
一种用于检测同型半胱氨酸结构荧光探针对位化合物应用,
a.化合物的稀释
称取上述化合物0.1g于1.5mlEP管中,加入1ml蒸馏水,溶解,混匀,梯度稀释至300倍;
b.化合物的荧光测定
取96孔黑色微孔板,加入上述化合物各100μl,激发光280nm,发射光590nm,测定其荧光强度;
c.同型半胱氨酸的荧光测定
取96孔黑色微孔板,加入同型半胱氨酸0μmol、1μmol、2μmol、5μmol、10μmol、20μmol、50μmol、和100μmol的同型半胱氨酸各100μl加入上述化合物各100μl,37度孵育10min,激发光280nm,发射光590nm,测定其荧光强度。
本例中实验材料与设备为细胞成像微孔板分析仪(C5MVDG)BioTek,美国。
探针与同型半胱氨酸反应后,扣除探针荧光自发荧光,可得到探针与同型半胱氨酸反应的线性图(图1)。(相关系数R=0.9985)
对其探针与同型半胱氨酸反应后荧光强度做重复性试验得到结果:
可得到试验结果稳定性高,实验结果可靠。
通过对荧光强度的测定可有效看出本探针可以和同型半胱氨酸结构中的氨基和琉基基团特异性的发生亲核加成反应,共辄体的空间结构发生变化,引起体系中荧光强度增强,可选择性检测同型半胱氨酸,与半胱氨酸和其它氨基酸不响应。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (2)
1.一种用于检测同型半胱氨酸结构荧光探针对位化合物,其特征在于,具有如下的结构:
2.一种用于检测同型半胱氨酸结构荧光探针对位化合物应用,其特征在于:
a.化合物的稀释
称取上述化合物0.1g于1.5mlEP管中,加入1ml蒸馏水,溶解,混匀,梯度稀释至300倍;
b.化合物的荧光测定
取96孔黑色微孔板,加入上述化合物各100μl,激发光280nm,发射光590nm,测定其荧光强度;
c.同型半胱氨酸的荧光测定
取96孔黑色微孔板,加入同型半胱氨酸0μmol、1μmol、2μmol、5μmol、10μmol、20μmol、50μmol、和100μmol的同型半胱氨酸各100μl加入上述化合物各100μl,37度孵育10min,激发光280nm,发射光590nm,测定其荧光强度。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810606849.1A CN108822070A (zh) | 2018-06-13 | 2018-06-13 | 一种用于检测同型半胱氨酸结构荧光探针对位化合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810606849.1A CN108822070A (zh) | 2018-06-13 | 2018-06-13 | 一种用于检测同型半胱氨酸结构荧光探针对位化合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108822070A true CN108822070A (zh) | 2018-11-16 |
Family
ID=64144894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810606849.1A Pending CN108822070A (zh) | 2018-06-13 | 2018-06-13 | 一种用于检测同型半胱氨酸结构荧光探针对位化合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108822070A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105339438A (zh) * | 2013-07-05 | 2016-02-17 | 富士胶片株式会社 | 色素多聚体、着色组合物、硬化膜、彩色滤光片、彩色滤光片的制造方法、固体摄像元件及图像显示装置 |
-
2018
- 2018-06-13 CN CN201810606849.1A patent/CN108822070A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105339438A (zh) * | 2013-07-05 | 2016-02-17 | 富士胶片株式会社 | 色素多聚体、着色组合物、硬化膜、彩色滤光片、彩色滤光片的制造方法、固体摄像元件及图像显示装置 |
Non-Patent Citations (1)
Title |
---|
SAMUEL SAS ET AL.: "Highly luminescent hybrid materials based on smectites with polyethylene glycol modified with rhodamine fluorophore", 《APPLIED CLAY SCIENCE》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Acaite et al. | The eradication experience of enzootic bovine leukosis from Lithuania | |
Varma et al. | Excretion of hydrogen peroxide in human urine | |
ES2609520T3 (es) | Péptidos novedosos para tratar y prevenir trastornos relacionados con el sistema inmunitario, incluyendo el tratamiento y la prevención de infecciones modulando la inmunidad innata | |
Spottiswoode et al. | Role of activins in hepcidin regulation during malaria | |
CN105866402A (zh) | 一种基于微球的杯式时间分辨荧光肌红蛋白分析试剂盒及其制备方法和应用 | |
ES2534330T3 (es) | Método de análisis biológico para anticuerpo contra el receptor de la hormona estimuladora tiroidea, kit de medición para el anticuerpo, y célula modificada genéticamente novedosa para su uso en el método de análisis biológico o en el kit de medición | |
Libisch et al. | Early Trypanosoma cruzi infection triggers mTORC1-mediated respiration increase and mitochondrial biogenesis in human primary cardiomyocytes | |
ES2352045T3 (es) | Diferenciación entre las meningitis bacterianas y víricas. | |
Ruzsanyi et al. | Diagnosing lactose malabsorption in children: difficulties in interpreting hydrogen breath test results | |
Kim et al. | Chemiluminescence imaging of Duox2-derived hydrogen peroxide for longitudinal visualization of biological response to viral infection in nasal mucosa | |
CN108794447A (zh) | 一种用于检测同型半胱氨酸结构荧光探针间位化合物及其应用 | |
Konduri et al. | Interaction of endothelial nitric oxide synthase with mitochondria regulates oxidative stress and function in fetal pulmonary artery endothelial cells | |
CN108822070A (zh) | 一种用于检测同型半胱氨酸结构荧光探针对位化合物及其应用 | |
Aguirre et al. | Functional evidence for nitric oxide production by skeletal-muscle mitochondria from lipopolysaccharide-treated mice | |
Langs-Barlow et al. | Association of circulating cytochrome c with clinical manifestations of antiretroviral-induced toxicity | |
WO2016159050A1 (ja) | 血液試料中のアンバウンドビリルビンの測定方法 | |
WO2016117618A1 (ja) | 慢性炎症性脱髄性多発神経炎の診断方法、キット及びバイオマーカー | |
ES2550158T3 (es) | Método para medir la actividad inhibidora sobre la unión ligando-receptor | |
JP2009536327A (ja) | 薬剤誘導肝臓損傷及び中毒性物質誘導肝臓損傷の同定及び早期同定並びに治療の同時観察のためのinvitro方法 | |
Li et al. | A novel near-infrared fluorescent probe for rapid sensing of HClO in living cells and zebrafish | |
ES2481517B1 (es) | Método para el diagnóstico de la enfermedad de parkinson en estadios tempranos | |
CN105974129A (zh) | 一步均相h-fabp检测试剂盒及其制备和使用方法 | |
CN107058625A (zh) | 用于鲑鳟鱼苗种鉴定的生物传感检测方法 | |
Briand et al. | Rapid detection of H. pylori Ag in human stool with the new bioNexia® H. pylori Ag test | |
Bonroy et al. | Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181116 |
|
WD01 | Invention patent application deemed withdrawn after publication |